Skip to Content

'
Khanh D. Vu, MD, F.A.C.P.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of General Internal Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

1999 The University of Texas Medical School at Houston, Houston, TX, MD, Internal Medicine
1995 The University of Dallas, Irving, TX, BS, Biology

Postgraduate Training

12/2011 Professional Development, Mid Career Women Faculty Professional Development Seminar, Association of American Medical Colleges, Austin, TX
7/1999-6/2002 Residency, Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX

Board Certifications

12/2022 Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles
1. Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC. A Randomized Controlled Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. e-Pub 5/2012. PMID: 22658895.
2. Dougherty PM, Cata JP, Burton AW, Vu K, Weng HR. Dysfunction in multiple primary afferent fiber subtypes revealed by quantitative sensory testing in patients with chronic vincristine-induced pain. J Pain Symptom Manage 33:166-79, 2/2007. PMID: 17280922.

Abstracts
1. Vu K, Yeung S-C, Thomas DA, Faderl S, Konopleva M, Busaidy N, Cabanillas M, Verma D, Escalante C, O'Brien S, Lavis V, Kantarjian H, Weiser MA. Effect of tight control of blood glucose during hyper-CVAD chemotherapy for acute lymphocytic leukemia. Blood 112(11):336 (#904), 2008.
2. Verma D, Faderl S, O'Brien S, Pierce S, Cortes J, Vu K, Freireich E, Keating MJ, Kantarjian HM, Ravandi F. Late relapses in acute myelogenous leukemia: Analysis of characteristics and outcome. Blood 112(11):350 (#951), 2008.
3. Faderl S, Thomas DA, Ravandi F, Garcia-Manero G, Beran M, Rytting M, Koller CA, Verstovsek S, Borthakur G, Andreeff M, Kornblau S, O'Brien S, Vu K, Kwari M. Intensification of Hyper-CVAD with L-Asparaginase, Vincristine, and Dexamethasone ("augmented Hyper-CVAD") has activity in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood 110(11):149b (#4324), 2007.
4. Vu KD, Hubbard JC, Lin E, Faderl SH, Cortes JE, O'Brien SM, Kantarjian HM, Thomas DA. Venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL) or lymphoblastic lymphoma (LL). Blood 110(11):152-153b (#4338), 2007.
5. Vu K, Thomas DA, Hubbard JC, Faderl S, Cortes J, Cabanillas ME, Garcia-Manero G, O'Brien SM, Kantarjian HM. Incidence of venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL) or lymphoblastic leukemia (LL). Blood 108(11) (#4534b), 2006.
6. Faderl S, Thomas DA, Garcia-Manero G, Ravandi F, Beran M, Rytting M, Koller CA, Verstovsek S, Borthakur G, Andreeff M, Kornblau S, Vu K, Jarmon R, Kantarjian HMK. Augmented hyper-CVAD in acute lymphoblastic leukemia and vincristine in adult ALL salvage: The MDACC experience with intensified L-asparaginase and vincristine in adult ALL salvage. Blood 106(11):523a, 2005.
7. Cabanillas, ME, Mattiuzzi G, Thomas D, Vu K, Ossa G, Garcia-Manero G, Cortes J, Giles F, O’Brien S, Kantarjian H. Invasive fungal infections (IFI) in patients (pts) receiving hyper-CVAD. J Clin Oncol 23:6727, 2004.
8. Quintas-Cardama, A, Kantarjian H, O’Brien S, Vu K, Garcia-Manero G, Giles F, Rios MB, Talpaz M, Cortes J. Administration of G-CSF (Filgrastim, NeupogenTM) for imatinib mesylate (GleevecTM)-induced neutropenia in chronic phase chronic myeloid leukemia (CML) patients (pts) is safe and facilitates the achievement of cytogenetic responses. Blood 102:906a, 2003.

Last updated: 1/11/2013